AbolerIS Pharma

Foundation date

28/11/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

Upcoming events

Latest news

  • Biocartis and SkylineDx sign collaboration to develop the Merlin Assay

    23 hours ago

  • Biotalys appoints Simon Moroney as Chairman of the Board

    1 day ago

  • Celyad Oncology appoints Dr. Charles Morris as Chief Medical Officer

    Tuesday April 20th 2021